SciLucent, Inc. (“SciLucent” or the “Company”) provides regulatory, scientific, and management consulting services to healthcare product companies across the pharmaceutical, biopharmaceutical, medical device, and dietary supplement industries. Since its founding in 1998, the Company has supported clients through product development, regulatory approval, and commercialization.
SC&H Capital advised SciLucent and its shareholders on the evaluation of strategic alternatives and the design and execution of a transaction resulting in a sale to an employee stock ownership plan. The ESOP structure aligned the interests of shareholders, employees, and clients while preserving the Company’s culture and positioning the business for continued growth under employee ownership.
